BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer

Mathieu Rouanne,1,2,3 Julien Adam,4,5 Camélia Radulescu,5 Diane Letourneau,1,7 Delphine Breidel,1 Séverine Mouraud,1 Anne-Gaëlle Goubet,1 Marion Leduc,1,8 Noah Chen,1 Tuan Zee Tan,10 Nicolas Signolle,11 Amélie Bigorgne,12,13 Michael Dussiot,12 Lambros Tselikas,1 Sandrine Susini,1 François-Xavier Danlos,1 Anna K. Schneider,10 Roman Chabanon,14,15 Sophie Vacher,16 Ivan Bieche,16 Thierry Lebret,3 Yves Allory,17,18 Jean-Charles Soria,3,12 Nicholas Arpaia,2,19 Guido Kroemer,8,9,20,21 Oliver Kepp,4,9 Jean Paul Thiery,11,22 Laurence Zitvogel,1,23 and Aurélien Marabelle13,23

1INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 2Department of Microbiology and Immunology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA. 3Département d’Urologie, Hôpital Foch, UVSQ – Université Paris-Saclay, Suresnes, France. 4Département de Biologie et Pathologie Médicales, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 5Département de Microbiologie et Immunologie, Hôpital Foch, UVSQ – Université Paris-Saclay, Suresnes, France. 6Université Claude Bernard Lyon I, Université de Lyon, Lyon, France. 7Département de Biologie, École Normale Supérieure de Lyon, Université Claude Bernard Lyon I, Université de Lyon, Lyon, France. 8Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, and 9Gustave Roussy, Université Paris-Saclay, Villejuif, France. 9Genomics and Data Analytics Core (GeDAC), Cancer Science Institute of Singapore, National University of Singapore, Singapore. 10INSERM U981, Gustave Roussy, Villejuif, France. 11INSERM U1163, Institut Imagine, Université de Paris, Paris, France. 12Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, France. 13ATIP-Avenir Group, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 14The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. 15Service de Génétique, Institut Curie, PSL Research University, Paris, France. 16Département de Pathologie, Institut Curie, Saint-Cloud, France. 17CNRS UMR144, Paris, France. 18Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA. 19Centre de Recherche des Cordeliers, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France. 20Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. 21Guangzhou Laboratory, Guangzhou, China. 22Centre d’Investigación Clínica de Biothérapies du Cancer (CICBT), Villejuif, France.

Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human bladder tumor samples, and data from cohorts of patients with bladder cancer before and after BCG therapy, we demonstrate 2 distinct patterns of immune subversion upon BCG relapse. In the first pattern, intracellular BCG infection of cancer cells induced a posttranscriptional downregulation of HLA-I membrane expression via inhibition of autophagy flux. Patients with HLA-I-deficient cancer cells following BCG therapy had a myeloid immunosuppressive tumor microenvironment (TME) with epithelial-mesenchymal transition (EMT) characteristics and dismal outcomes. Conversely, patients with HLA-I-proficient cancer cells after BCG therapy presented with CD8+ T cell tumor infiltrates, upregulation of inflammatory cytokines, and immune checkpoint–inhibitory molecules. The latter patients had a very favorable outcome. We surmise that HLA-I expression in bladder cancers at relapse following BCG does not result from immuneediting but rather from an immune subversion process directly induced by BCG on cancer cells, which predicts a dismal prognosis. HLA-I scoring of cancer cells by IHC staining can be easily implemented by pathologists in routine practice to stratify future treatment strategies for patients with urothelial cancer.

Conflict of interest: Over the past 2 years, JCS has received consultancy fees and shares from Relay Therapeutics and Gritstone bio; was on the board of directors of Hookipa Pharmaceuticals (2018–2021); was full-time employee (2017–2019) at AstraZeneca; and has been a full-time employee at Amgen since August 2021. Over the past 7 years, AM has received institutional funding grants from AstraZeneca, Merus, Bristol-Myers Squibb (BMS), Boehringer Ingelheim, Transgene, Fondation MSD Avenir, and Sanofi; is a member of the Clinical Trial Steering Committee for NCT02528357 (GliaxSmithKline [GSK]), NCT03334617 (AstraZeneca); is a member of the Data Safety and Monitoring Board for NCT02423863 (sponsor: Oncovir) and NCT0318685 (sponsor: Centre Léon Bérard); has participated on the scientific advisory boards of the following companies: Merck Serono, eTheRNA, Lytx Biopharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, AstraZeneca/MedImmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX Pharma, OSE Immunotherapeutics, MediciX, HiFiBio, iMedCheck, MSD, Innate Pharma, and HotSpot Therapeutics; has received teaching/speaker honoraria from Roche/Genentech, BMS, Merck (MSD), Merck Serono, AstraZeneca/MedImmune, Amgen, Sanofi, and Servier; has received fees for scientific and medical consulting from Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Gentecel, Rigontech, Dalichi Sankyo, Imxiao, Sanofi/BioNTech, Molecular Partners, Pillar Partners, Benta Pharma Industries (BPI), and Faron; has received nonfinancial support (travel expenses) from AstraZeneca, BMS, Merck (MSD), and Roche; is co-founder and shareholder of Centessa; holds a patent titled “Humanized and chimeric monoclonal antibodies to CDB1” (US patent application serial no. 62/391,054); LZ is founder of Everimmune, a cancer/microbiome biotechnology company; is a member of the board of directors of Transgene; is a member of the scientific advisory board of Transgene, EpiVax, Lytx Biopharma; has received past research contracts with Merus, Roche, and Tusk and honoraria from Transgene; has current research contracts with Innova Pharm, Kaleido, Pileje, Incyte, BMS, GSK, and Transgene; and is an employee of Gustave Roussy and the Faculté de Médecine Paris XI. CK is on the board of directors of the BMS Foundation (France); receives grants and research support from Dalichi Sankyo, Eleoer, Kaleido, Lytx Pharma, PharmaMar, Samsara, Sotio, and Vascularis/Tioma; is founder and shareholder of Everimmune. Osasuna Therapeutics, Samsara Therapeutics, and Therafast Bio; is an employee of the University of Paris, AP-HP, Gustave Roussy. OK receives grant and research support from Dalichi Sankyo, Eleoer, Kaleido, Lytx Pharma, PharmaMar, Samsara, Sotio, and Vascularis/Tioma; is founder and shareholder of Samsara Therapeutics; and is an employee of INSERM, Gustave Roussy. JPT is the scientific founder and chairman of BioCheetah Pte Ltd (Singapore), a company involved in urine-based bladder cancer diagnostics. LT has received research grants from the BMS Foundation and Terumo and honoraria or consulting fees from Boston Scientific, General Electric, and Ipsen.
Introduction

Bladder cancer is a heterogeneous disease that displays invasive and noninvasive histological features of the urothelium, as well as a wide spectrum of molecular alterations and subtypes (1, 2). Treatment of noninvasive tumors with high-risk features (carcinoma in situ [CIS], high-grade Ta [cancer cells involving the urothelium, the innermost layer of the bladder mucosa], any T1 [cancer cells involving the lamina propria, the connective tissue beneath the urothelium]) includes transurethral resection of the tumor, followed by intravesical instillations of bacillus Calmette-Guérin (BCG) (3). The origin of BCG traces back to the determined and perseverant work of Albert Calmette and Camille Guérin, who developed an attenuated form of live Mycobacterium bovis after 13 years of culturing and 231 passages (4). Today, BCG is still the only available vaccine against tuberculosis and one of the most successful cancer immunotherapies used as a standard adjuvant therapy for high-risk, nonmuscle-invasive bladder cancer (NMIBC). Despite a multitude of evidence for antitumor efficacy, half of the patients with high-risk NMIBC eventually develop tumor recurrence, and up to 30% of these patients will progress to secondary muscle-invasive bladder cancer (MIBC). Ultimately, 10% to 15% of patients die of metastatic disease (5, 6). Patients with secondary MIBC following BCG immunotherapy have worse oncological outcomes as compared with those with de novo primary MIBC. Additionally, such patients would not benefit from current standard cisplatin-based neoadjuvant chemotherapy, which suggests that tumor escape from intravesical BCG immunotherapy may select clones that are resistant to subsequent systemic chemotherapy (7).

Although recent studies have identified potential immune parameters that could affect the clinical response, the mechanisms of tumor resistance to BCG immunotherapy remain poorly understood (8–13). Indeed, modeling early-stage bladder cancer in mice is particularly challenging because of the rapid tumor growth inside the murine bladder wall (14). Additionally, tumor heterogeneity and the plasticity of urothelial cancer cells undermine our attempts to decipher the dynamics of immune escape under selective pressure. How urothelial cancer cells evade the antitumor immune response and whether such urothelial cancer cells could acquire extrinsic or intrinsic immune escape mechanisms upon BCG exposure remain unknown. Altogether, this highlights the crucial need for a more thorough understanding of the mechanisms of resistance to BCG immunotherapy to better stratify bladder cancer treatment strategies and identify new targetable pathways.

In this study, we investigated the effects of BCG immunotherapy on the biology of bladder cancers. We identified 2 distinct patterns of immune resistance after BCG exposure and propose a biologically relevant and clinically feasible stratification strategy for the treatment of patients with tumors progressing after intravesical BCG immunotherapy.

Results

Ex vivo BCG stimulation of fresh human bladder tumors and cancer cell lines induces HLA-I downregulation on cancer cells. The immune escape mechanisms of cancer cells following intravesical BCG remain poorly understood in patients with bladder cancer. To assess the effects of BCG on tumor-derived bladder cancer cells, we coincubated therapeutic BCG for 72 hours with whole-cell suspensions generated from mechanically and enzymatically dissociated fresh human bladder tumors (Figure 1A). All the samples were obtained from patients with clinically localized bladder tumors who were undergoing curative intent surgery (n = 12; Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI145666DS1). By flow cytometry, we could then assess separately the proportions and effects of BCG on CD45 EpCAM+ bladder cancer cells and CD45+EpCAM− WBCs from the same tumors (Figure 1B and Supplemental Figure 1). Although we expected to see most of the biological effects of BCG to occur on the WBC compartment, we found that coincubation with BCG induced a significant drop in the proportion of CD45 EpCAM+ cells expressing membrane HLA-I (Figure 1C). This diminution in the proportions of HLA-I+ cells was also associated with a significant diminution of HLA-I MFI, which reflects the total number of HLA-I molecules expressed on the outer membrane of cells (Figure 1D, left panel). This BCG effect on HLA-I expression was more dramatic in some tumors than in others (Figure 1D, middle and right panels) and was not found to be significant on WBCs (Supplemental Figure 1B). To explore the ability of BCG to activate lymphoid and myeloid cells in situ, we assessed the phenotype of CD45+ immune cells 72 hours after coculturing with BCG. We observed a drastic diminution of CD45+ immune cells 3 days after BCG exposure (Supplemental Figure 1C). However, we observed no variation among the immune cell subsets within the CD45+ cells. Therefore, the absolute quantity of immune cells after 72 hours of BCG exposure was diminished, but the relative proportion of lymphoid CD3+ T cells, CD20+ B cells, CD56+ NK cells, and CD11b+ myeloid cell subsets among live CD45+ cells remained stable in the BCG condition compared with the medium and IFN-γ controls (Supplemental Figure 1C). Additionally, the relative proportions of CD4+ and CD8+ T cells among live CD3+ T cells, together with FoxP3+ cells among live CD4+ T cells, were also stable (Supplemental Figure 1C). Next, we evaluated the activation of immune cells by looking at the relative proportions of HLA-DR+ cells in CD11b+ and CD69+ cells and programmed cell death 1-positive (PD-1+) cells in CD3+ T cells. We observed no difference across conditions (Supplemental Figure 1D). Overall, we found that BCG did not induce activation markers on the surface of lymphoid or myeloid cells in the early-stage bladder tumors. However, BCG could induce a marked diminution of HLA-I molecules expressed on the surface of cancer cells.

BCG induces a downregulation of HLA class I molecules on some cancer cells. To further investigate the effect of BCG on HLA-I expression by cancer cells, we exposed in vitro low-grade (RT4,
significant decrease in MFI for both HLA-I molecules (HLA-A/-B/-C subsets) and β2 microglobulin (β2m) in high-and low-grade cancer cells 24 hours after BCG coincubation (Figure 1G and Supplemental Figure 1, F and G). Altogether, we confirmed that BCG induced HLA-I downregulation in a subset of cancer cells early (24 hours) and high-grade (SW780, 5637, HT1376, TCCSUP, and UM-UC3) human bladder cancer cell lines to therapeutic BCG (Figure 1E). We confirmed that HLA-I deficiency occurred in a subset of cancer cells in all of the 6 cell lines tested (Figure 1F and Supplemental Figure 1E). Similarly to the ex vivo data, we observed a concomitant.

Figure 1. BCG induces HLA-I downregulation on cancer cells. (A) Cell suspensions from freshly dissociated human bladder tumors were cultured in triplicate in complete medium (untreated), stimulated with IFN-γ, or coincubated with BCG. (B) Gating strategy adopted to detect CD45+ immune cells and CD45+EpCAM+ cancer cells by flow cytometric analysis. (C) Proportions of HLA-I+CD45+EpCAM+ cells among live tumor cells following ex vivo BCG or IFN-γ stimulation of fresh human tumors (n = 12; 1-way ANOVA with Tukey’s post test). (D) MFI of HLA-I on live CD45+EpCAM+ cancer cells upon ex vivo BCG or IFN-γ exposure (n = 12 paired samples; 1-way ANOVA with Tukey’s post test). (E) High-grade (n = 4) and low-grade (n = 2) human bladder cancer cell lines were cultured in vitro in triplicate under 3 conditions: untreated, stimulated with IFN-γ, or coincubated with BCG. (F) Histogram showing HLA-I downregulation in a subset of cancer cells upon BCG exposure. (G) HLA-I MFI by flow cytometry 24 hours after in vitro BCG or IFN-γ exposure (n = 3 conditions per cell line; 1-way ANOVA with Tukey’s post test). (H) HLA-I and HLA-I+ cancer cells were sorted after 24 hours of coincubation with BCG. HLA-I and HLA-I+ cancer cells were cultured in BCG-free medium for 6 additional days, followed by flow cytometric analysis on day 7 to measure HLA-I expression on the cancer cells. (I) Sustained HLA-I MFI of cancer cells after 6 days in BCG-free medium. Left inset: Illustrative MFI from HLA-I+ (blue) and HLA-I– (red). Graph shows cumulative data points of HLA-I MFI from 5 distinct cancer cell lines (n = 5 independent experiments using RT4, 5637, HT1376, TCCSUP, and UM-UC3 cancer cell lines; unpaired, 2-tailed t test). (J) HLA-I+ and HLA-I– cancer cells were restimulated with IFN-γ for 24 hours after 3 days of culturing in BCG-free medium (1-way ANOVA with Tukey’s post test). All data are presented as the mean ± SEM. *P<0.05, **P<0.005, ***P<0.001, and ****P<0.0001.
hours) after BCG exposure, independently of the presence of the immune and stromal cell compartments. We next evaluated whether HLA-I downregulation was sustained over time. To test this approach, we sorted cancer cells on the basis of HLA-I expression 24 hours after BCG exposure. Subsequently, we cultured HLA-I+ and HLA-I– cells independently in BCG-free medium for 6 days (Figure 1H) and then analyzed HLA-I expression by flow cytometry on day 7. We still observed a significant reduction in HLA-I MFI in HLA-I– cells (Figure 1I), which was not reversible by IFN-γ exposure (Figure 1J). Collectively, these data demonstrate that BCG may shape the immunogenicity of cancer cells, independently of the tumor immune microenvironment, by downregulating their membrane expression of HLA-I and β2m antigen-presenting molecules.

**BCG induces EMT characteristics in the subset of HLA-I– cancer cells.** Next, we investigated whether cancer cells with BCG-induced HLA-I downregulation (HLA-I–) have specific characteristics in comparison with HLA-I+ cancer cells upon ex vivo exposure of fresh human bladder tumors to BCG (Figure 2A). First, we assessed the proliferative activity and apoptosis of cancer cells according to their HLA-I membrane expression as assessed by flow cytometry. Interestingly, the percentage of Ki67+ cells did not differ according to HLA-I expression (Figure 2B). However, we observed a significant diminution of epithelial cellular adhesion molecule (EpCAM) membrane expression by MFI and a lower proportion of annexin-V– cells within HLA-I+ cancer cells (Figure 2B, middle and right panels, respectively). Together, these data suggested that BCG-induced HLA-I downregulation could be associated with apoptosis resistance and acquisition of mesenchymal characteristics in cancer cells.

To further evaluate the link between HLA-I and EpCAM expression, we measured the membranous coexpression of HLA-I and EpCAM by flow cytometry on a broad range of bladder cancer cell lines, ranging from an epithelial to a mesenchymal phenotype (Figure 2C). Additionally, HLA-I EpCAM+ cells were characterized by lower forward scatter (FSC-A) and side scatter (SSC-A), cell shrinkage, flattened bodies, and loss of intercellular adhesion in contrast to the parental cell line (Supplemental Figure 2, A and B). As seen with HLA-I downregulation, EpCAM loss was maintained over time (Supplemental Figure 2C). Importantly, these data suggest that BCG could induce an epithelial-mesenchymal transition (EMT) in a subset of cancer cells.

To better explore this hypothesis, we analyzed the EMT status of cancer cells 24 hours after BCG coincubation. In this experimental study, we used 3 cell lines with the most extreme EMT status (as previously defined by a quantification algorithm [ref. 15] and as outlined in Supplemental Figure 2D), including the epithelial cell line RT4, the mesenchymal cell line UM-UC3, and the 5637 cancer cell line with intermediate EMT status (Supplemental Figure 2, A and B). To identify a shift toward a mesenchymal state, we sorted the HLA-I+ and HLA-I– cancer cells 24 hours after BCG exposure and extracted RNA from these 2 cell subsets (Figure 2D). We next calculated the EMT score of HLA-I+ and HLA-I– cells for each cancer cell line on the basis of their HLA-I and β2m antigen-presenting molecules.

**BCG induces greater inflammatory responses in HLA-I+ cancer cells than in HLA-I– cells, and these responses are further enhanced upon BCG reexposure.** To better characterize the biology of cancer cells according to their HLA-I status after BCG exposure, we investigated the levels of cytokines and chemokines released by cancer cells 24 hours after BCG exposure. Bladder cancer cells were sorted on the basis HLA-I expression after 24 hours of exposure to BCG and were cultured independently in BCG medium–free environment for an additional 72 hours (Figure 3A). Supernatants were then titrated for their cytokine and chemokine content. We found strong differences in the secretory profile of HLA-I+ and HLA-I– cancer cells (Figure 3, B and C, and Supplemental Figure 3). Importantly, HLA-I+ cancer cells secreted sustained levels of the chemotactic factors CXCL10, CCL4, CCL5, and IFN-γ cytokine in contrast to the HLA-I– cancer cells (Figure 3B). Overall, these results demonstrated that the release of T cell chemotactants was high in HLA-I+ cancer cells upon BCG exposure but very low in HLA-I– cancer cells.

To test whether the restimulation of cancer cells with BCG would enhance their cytokine production, we coincubated cancer cells with BCG for 24 hours. Then, cells were cultured in BCG-free medium for 5 days. On day 6, the cancer cells were restimulated with BCG for 24 hours (Figure 3D). We observed dramatic increases in the levels of CXCL10 and CCL5 release upon a
Figure 2. BCG induces EMT characteristics in the subset of HLA-I- cancer cells. (A) Flow cytometric dot plot showing HLA-I+ and HLA-I- cancer cells among live cells following ex vivo BCG stimulation of fresh human tumors for 72 hours. (B) MFI of EpCAM (n = 12; 1-way ANOVA with Tukey’s post test) and relative proportions of proliferative Ki67+ and apoptotic annexin-V+ cells (n = 12; paired, 2-tailed t test) among live cancer cells by flow cytometry. (C) Flow cytometric dot plots for HLA-I+ and EpCAM expression in live cancer cells. Dot plots illustrate the control condition at the top and the BCG condition at the bottom. Cancer cells were ordered according to their baseline expression of EpCAM (MFI), ranging from the left (epithelial type, RT4) to the right (mesenchymal type, UM-UC3). (D) Cancer cells (RT4, 5637, and UM-UC3) were coincubated with BCG for 24 hours and sorted on the basis of their HLA-I membrane expression. Total RNA extraction of HLA-I+ and HLA-I- cancer cells was performed. (E) The EMT score based on NanoString IO360 transcriptomic data was obtained for HLA-I- cancer cells. HLA-I- 5637 cancer cells showed the strongest shift toward a mesenchymal score. (F) Unsupervised hierarchical clustering analysis of cancer cells according to EMT status, depicted per cell line (columns), HLA-I status (columns), and genes expressed (rows). (G) Epithelial (CDH1 [E-cadherin] and EPCAM) and mesenchymal (CDH11) absolute mRNA expression after BCG (red, EMT+: 5637 HLA-I-; green, EMT-: RT4 and 5637 HLA-I+). Unpaired, 2-tailed t test. All data are presented as the mean ± SEM. *P < 0.05, **P < 0.005, ***P < 0.001.
The proportion of HLA-I+ cells remained unchanged (Figure 3E). Overall, these data provide evidence that the cancer cells primed with BCG displayed a stronger recall response upon BCG reexposure.

BCG-infected cancer cells downregulate HLA class I and EpCAM membrane expression. We explored the mechanism by which BCG induced HLA-I downregulation on cancer cells. BCG is known to activate TLR2, TLR4, and TLR9 (16). Therefore, we investigated whether HLA-I downregulation was directly dependent on whole, live bacteria or if it could be induced directly by the activation of TLR2, TLR4, and TLR9. To address this question, we compared the effects of live attenuated strains of BCG with synthetic agonists of TLR2, TLR4, and TLR9. Of note, neither TLR agonists alone nor in combination could induce HLA-I downregulation on cancer cells (Supplemental Figure 4A). These data suggest that live bacteria rather than TLR stimulation are required to induce HLA-I downregulation in cancer cells.

Because mycobacteria can reside within eukaryotic cells, we hypothesized that live bacteria from therapeutic BCG could infect cancer cells. First, we stained a coculture of bladder cancer cells and BCG with Ziehl-Neelsen dye and could detect some BCG bacteria within the cytoplasm of cancer cells (Figure 4A). Next, we used calcein to confirm the presence of live bacteria in the therapeutic BCG. Calcein is a fluorescent dye that can be transported through the cellular membrane into live organisms, which makes it useful for testing the viability of bacteria and tracking intracellular infection by live bacteria. To determine whether either live or dead BCG was required to observe the effect on cancer cell HLA-I downregulation, we first evaluated the best way—heat or UVB exposure—to eradicate viable (calcein+) BCG. We found that heat was the most efficient technique to kill BCG (Supplemental Figure 4C). To assess whether live bacteria from therapeutic BCG was able to enter cancer cells, we coincubated calcein-labeled BCG together with...
gene expression in cells classified as HLA-I + or HLA-I – by protein-based on their HLA-I status upon BCG exposure. This analysis to lower expression of HLA-I genes. We performed NanoString HLA-I, we tested the hypothesis that this effect could be related understand the mechanism of BCG-induced downregulation of phenomenon associated with inhibition of autophagy flux. This phenomenon is an inhibition of the degradation of autophagosomes, which can intervene at several levels: recruitment of lysosomes, fusion of lysosomes with autophagosomes, or degradation of autolysosomes. Autophagosomes then accumulate in the cytoplasm and aggregate. This question was subsequently tested on the LC3-GFP plus RFP tandem cell line, which allows one to track the generation of autophagolysosomes and study autophagy fluxes. We found an accumulation of autophagolysosomes in the cytoplasm of U2OS cancer cells in favor of an autophagy flux inhibition (Figure 5F). Inhibition of the autophagy flux was found to be BCG dose dependent after 12 hours of BCG coculturing with U2OS cells (Figure 5G). Altogether, we found that BCG-induced HLA-I downregulation was associated with inhibition of autophagy flux.

Two distinct mechanisms of cancer cell immune escape steer the outcome of BCG immunotherapy. To determine whether HLA-I downregulation upon BCG therapy indeed occurred in vivo and affected the outcome of patients with bladder cancer, we studied a cohort of 27 patients who relapsed after BCG immunotherapy. These patients were first treated with intravesical BCG for high-risk NMIBC, which subsequently progressed to MIBC (Figure 6A and Supplemental Table 5). Longitudinal tumor samples obtained from paired primary and secondary bladder tumors before and after BCG were collected for analyses. To identify specific alterations of the immune microenvironment associated with acquired resistance to BCG, we performed in situ immune profiling using a predefined NanoString panel of 730 immune and inflammatory gene products and a 6-marker IHC panel (Supplemental Figure 6). We first measured the evolution of HLA-I expression on cancer cells before BCG therapy and upon relapse after BCG therapy in paired tumor samples (Figure 6B). Although there was no obvious difference between the pre-BCG and post-BCG relapse levels of HLA-I expression in tumors (Supplemental Figure 7A), upon paired analysis of the tumor samples, we detected a profound downregulation of HLA-I on cancer cells in half of the tumor cohort (n = 13 of 27) (Figure 6C). By contrast, HLA-I upregulation occurred in the second half (n = 14 of 27) of the cohort. Then, we hypothesized that the tumor’s HLA-I phenotype could affect the in situ inflammatory responses and subsequently orchestrate a specific tumor immune microenvironment. To test this hypothesis, we evaluated the differential gene expression profiles before BCG therapy and
Figure 4. BCG-infected cancer cells downregulate HLA-I and EpCAM membrane protein expression. (A) Ziehl-Neelsen staining for UM-UC3 cancer cells coincubated with BCG (MOI of 10) for 24 hours showed isolated bacteria inside cancer cells and agglomerates of BCG outside of cancer cells. Scale bar: 20 μm. (B) Experimental setting to evaluate the coincubation of cancer cells (RT4, 5637, UM-UC3) with calcein-labeled BCG. (C) Intracytoplasmic visualization of calcein-labeled BCG inside the cytoplasm of cancer cells. Original magnification, ×60. (D) Immunofluorescence staining of HLA-I (red), and calcein (green) in human bladder cancer cells following in vitro exposure to calcein-labeled BCG, heat-killed, calcein-labeled BCG, or IFN-γ for 24 hours. Original magnification, ×63. (E) HLA-I MFI quantification per confocal image analysis on cancer cells cocultured with heat-killed or live BCG. HLA-I MFI data is given for every single cell acquired for untreated (n = 244 cells), BCG (n = 239), heat-killed BCG (n = 160), and IFN-γ (n = 175). Only live BCG induced a significant downregulation of HLA-I expression on cancer cells (1-way ANOVA with Tukey’s post test). (F) MFI for HLA-I and EpCAM in BCG infected (intracellular calcein-BCG+) versus noninfected (calcein-BCG−) cancer cells. Controls were untreated cancer cells (1-way ANOVA with Tukey’s post test). (G) Representative images of BCG-uninfected, BCG-infected, and BCG-noninfected cancer cells 24 hours after BCG coincubation. Original magnification, ×60. (H) Spearman’s correlation for the MFI of HLA-I and EpCAM in 100 cancer cells, 24 hours after BCG coincubation. (I) HLA-I and EpCAM expression on melanoma (MEL888), lung (A549), colorectal (HCT116), and cervical (HeLa) carcinoma cells when cultured with control media, heat-killed BCG, or live BCG. Relative proportion of HLA-I− cancer cells (percentage) among live cells (1-way ANOVA with Tukey’s post test). (J) Proportion of HLA-I− cells upon 24 hours of coincubation with either heat-killed or live BCG on HELA, HCT116, MEL888, and A549 cancer cell lines (1-way ANOVA with Tukey’s post test). Data are presented as the mean ± SEM. *P < 0.05, **P < 0.001, and ****P < 0.0001.
following BCG relapse after segregating the tumors according to whether HLA-I expression increased or decreased upon treatment (Figure 6D and Supplemental Figure 6).

We identified a significant upregulation of genes expressed by T cells (CD8+, CD4+) and of their immune-checkpoint inhibitory receptors in relapsing tumors following BCG immunotherapy (Supplemental Figure 7B). However, looking separately at the transcriptome from tumors with either an up- or downregulation of HLA-I, we discovered that CTLA4, TIGIT, LAG3, programmed death ligand 1 (PD1), PD1, and IDO1 genes were selectively upregulated in tumors, which maintained or increased their HLA-I expression after BCG therapy (Figure 6E). In contrast, tumors that showed downregulation of HLA-I expression after BCG therapy did not have significantly modified levels of T cell immune checkpoint expression (Figure 6F). Additionally, we identified a distinct set of genes differentially expressed according to their tumor HLA-I subtypes (Figure 6D). Notably, we observed a “myeloid-suppressive” type of immune microenvironment with increased levels of CD163, CSF-1R, CSF-3R, and IL-10 expression in tumors expressing low levels of HLA-I following BCG relapse (Figure 7A, upper panel).

In contrast, tumors with strong HLA-I expression were associated with a “T cell–suppressive” type of immune microenvironment characterized by increased levels of CD8A, GZMB, PFR1, and IFNG gene expression after BCG (Figure 7A, lower panel). Furthermore, we observed in this latter subgroup a significant upregulation of CXCL9/-10/-11, CCL4, and CCL5 chemokine expression, together with their specific receptors CXCR3 and CCR5 (Figure 7A, lower panel). Next, we evaluated the EMT score in serial tumor samples, starting from BCG-naive NMIBC to muscle-invasive progression and distant metastatic disease after BCG therapy. Similar to our in vitro data, we found that an increase in the EMT score correlated with downregulation of HLA-I expression over the progression of the disease (Supplemental Figure 7C).

To further validate our findings at the protein and cellular levels, we investigated the evolution of tumor-infiltrating lymphocytes (TILs) by IHC before and after BCG (Supplemental Figure 7D). Again, we could not find overall changes for those markers in tumors before BCG or after BCG relapse (Supplemental Figure 7E). However, when we looked at the data in a paired manner, we confirmed that CD8+ T cells and PD-L1 were significantly increased on immune cells in tumors expressing high levels of HLA-I at relapse following BCG (Figure 7B, lower panel). In contrast, no variation of TILs or PD-L1 expression were observed in the HLA-I–deficient tumors at relapse following BCG (Figure 7B, upper panel). However, we observed increased intratumoral CD163+ macrophages in those HLA-I–deficient tumors, consistent with our findings at the mRNA level (Figure 7B, pie charts in the upper panel), and which we did not observe in the HLA-I–tumors (Figure 7B, pie charts in the lower panel). Of note, when we analyzed genes related to γ-δ T cells and NK cells (Supplemental Table 6), we found disparate variations but no significant change in gene expression levels across patients and could not find a clear association with their HLA-I tumor status (Supplemental Figure 7, F and G). Taken together, these data provide evidence that specific types of immune escape mechanisms are associated with the level of expression of HLA-I in tumors resistant or refractory to BCG immunotherapy.

Finally, we hypothesized that the level of HLA-I expression in tumors could impact the clinical outcome of patients with bladder cancer. To test this hypothesis, we identified which patients eventually developed distant metastasis or died from their bladder cancer in our cohort. With a 5-year follow-up, we found that 69% (n = 9 of 13) of the patients who had downregulated HLA-I levels in their tumor after BCG developed distant metastases (Figure 7, C and D). In contrast, only 14% (n = 2 of 14) of the patients developed metastases when HLA-I expression was maintained or upregulated in tumors at relapse after BCG during the same follow-up period. Furthermore, we observed a large difference in distant metastasis–free survival (DMFS), with a median DMFS of 27 months for patients with HLA-I tumors versus survival not reached for patients with HLA-I–tumors (log rank P = 0.001). We also observed large differences in cancer-specific survival (CSS) and overall survival (OS) according to the tumor’s post-BCG HLA-I status. The median CSS and the median OS were both 37 months for HLA-I patients versus survival not reached for HLA-I–tumors (log rank P = 0.0006 and P = 0.003, respectively; Figure 7E). Taken altogether, this set of data illustrates that, at relapse, patients with downregulated HLA-I expression upon BCG therapy experience immune surveillance escape in their TME and have dismal outcomes.

Discussion

Although conclusions from retrospective series of patient tumor samples can only be correlative, we show here that the HLA-I status of tumors that progress after intravesical BCG therapy defines 2 biologically distinct subgroups of patients with opposite outcomes. These observations suggest the existence of 2 different mechanisms of resistance to BCG therapy. In the first pattern, cancer cells have upregulated HLA-I protein expression upon BCG therapy and display increased numbers of CD3+CD8+ T cells in the TME, present a cytotoxic IFN-γ signature, and show T cell checkpoint upregulation. In the other pattern, tumors show downregulation of HLA-I protein expression upon BCG therapy, display no changes in T cells in their TME, and present an immunosuppressive myeloid profile. Our in vitro assays on fresh human bladder tumors and cancer cell lines demonstrated the causative effect of BCG on HLA-I downregulation by cancer cells, and the differential phenotype induced by BCG in terms of cytokine/chemokine and EMT profiles in cancer cells that have either upregulated or downregulated expression of their HLA-I molecules upon BCG exposure. Moreover, we show that live bacteria contained in clinical-grade BCG have the capacity to directly infect cancer cells. To the best of our knowledge, this capacity has only been demonstrated in vitro upon coincubation of live BCG strains expressing GFP (17). For the first time to our knowledge, we report this observation in our study using clinical-grade BCG, which contains a predominance of killed mycobacteria (18). Although live BCG is required to trigger the recruitment of T cells to the bladder microenvironment, the importance of the ratio of live versus dead mycobacteria has not been formally evaluated (11). Also, our results show that different human cancer cell lines have different sensitivities to BCG. One hypothesis, which would explain this observation, is that intracellular uptake of BCG by cancer cells could be dependent on their underlying level of kinase oncogenic stress. Indeed, using GFP-expressing BCG, Redelman-Sidi et al. demonstrated...
such as those for phosphoinositide 3 kinase and RAS via microphagocytosis-dependent on the oncogenic activation of signaling pathways effector kinase Pak1. They showed that cancer cell uptake of BCG that BCG entry into cancer cells relies upon Rac1, Cdc42, and their downregulation of HLA-I and BCG induced a rapid (within 24 hours), profound, and sustained fates seem to be associated with the regulation of HLA-I surface expression in cancer cells upon BCG exposure. Several key conclusions can be drawn from these results. First, in ex vivo fresh human bladder tumors, we found that BCG had no effect on the activation phenotype of TILs, a finding consistent with observations made in an immune-competent orthotopic model of bladder cancer (20). However, our findings show that BCG induced a rapid (within 24 hours), profound, and sustained downregulation of HLA-I and β2m expression in ex vivo fresh human bladder tumors and in in vitro experimental data using several cancer cell lines. Interestingly, prior studies have shown that mycobacteria evade the host-adaptive immune response through multiple mechanisms. Specifically, live mycobacteria tuberculosis may escape immune control through inhibition of class I and class II MHC antigen processing in infected cells upon TLR signaling (21, 22). To our knowledge, the ability of live M. bovis BCG to infect cancer cells and orchestrate tumor immune suppression through HLA-I downregulation and a TLR-independent pathway has not previously been reported.

Importantly, we surmise that HLA-I downregulation in bladder cancers does not result from immunoediting but rather from an intracellular bacteria-induced EMT process that predicts a dismal prognosis. A lack of HLA-I expression by cancer cells is currently recognized as a hallmark of a cancer immunoediting process induced by TILs (23). Paradoxically, we found in our clinical cohort that half of the BCG-resistant tumors were associated with HLA-I upregulation and a Th1 type of tumor-infiltrative immune response. In contrast, we observed poor T cell infiltration in HLA-I-deficient tumors. Also, 2 distinct profiles of inflammatory cytokine/chemokine expression and secretion were identified in vitro when exposing the cancer cell lines or fresh bladder tumors to BCG. Those profiles were again associated with HLA-I expression levels in cancer cells. While HLA-I+ cancer cells released key effector cytokines and chemokines, such as CXCL10, CCL4, CCL5, and IFN-γ, HLA-I-deficient cancer cells had a limited release of proinflammatory cytokines. Building on these findings, we suggest that BCG can directly affect the immunogenicity of cancer cells, which subsequently orchestrate a distinct type of bladder cancer immune microenvironment. In situ immune profiling of BCG-resistant tumors strengthened this hypothesis. Specifically, HLA-I+ tumors displayed an in situ cytotoxic CD8+ T cell response, with the CXCL9/CXCL10/CXCL11/CXCR3 axis contributing to immune cell migration, activation, and differentiation. Additionally, the expression of multiple inhibitory receptors such as CTLA-4, TIGIT, LG3, PD-1, and PD-L1 suggests that the tumor-acquired resistance was associated with T cell exhaustion in BCG-induced HLA-I+ tumors. By contrast, HLA-I-deficient tumors displayed an immunosuppressive microenvironment characterized by the upregulation of myeloid markers (CD163, CSF1R, CSF3R) and M2 macrophage–related cytokines (CCL18, IL-10) associated with CD8+ T cell exclusion from the TME. This observation led us to characterize a second mechanism of acquired resistance to BCG immunotherapy in HLA-I-deficient tumors. Our data support prior studies suggesting that immune suppression of the bladder microenvironment enriched with myeloid-derived suppressive cells (9) acquired upon BCG exposure may limit clinical-grade BCG efficacy and favor tumor recurrence. Hence, we identified 2 distinct patterns of immune escape following exposure to BCG and propose a biologically relevant and clinically feasible stratification strategy for the treatment of patients with BCG-unresponsive bladder tumors.

Of note, it might not be fortuitous that syngeneic and transplantable MB49 and UPPL1541 murine cancer cell lines were both found to be HLA-1. Indeed, this feature may provide the immune escape mechanism required to have transplantable properties (invariably in males and females). Sun et al. showed also that...
Figure 6. Cancer cell HLA-I downregulation upon BCG therapy is associated with an absence of T cell checkpoint modulation in the TME. (A) A longitudinal cohort of patients with BCG-resistant or refractory bladder cancer was identified (n = 27). Paired bladder tumors were evaluated before and after BCG immunotherapy–acquired resistance. (B) Representative images of HLA-I+ or HLA-I– IHC stainings from bladder tumors with acquired resistance to BCG immunotherapy. Scale bar: 50 μm. (C) Relapsing/refractory bladder tumors displayed either downregulation (red) or upregulation (blue) of HLA-I upon BCG immunotherapy (1-way ANOVA with Tukey’s post test). (D) Venn diagram depicting the number of upregulated transcripts (P < 0.05) between paired tumors before and after BCG (n = 6) according to the evolution of HLA-I expression at the proteomic (i.e., IHC) level (left circle, number of upregulated genes in tumors with decreased HLA-I; right circle, number of upregulated genes in tumors with increased HLA-I). Only genes differentially upregulated (i.e., P < 0.05; log2 fold change ≥2) before and after BCG immunotherapy were selected from the NanoString analysis. (E and F) Paired representation of the absolute expression of immune checkpoint inhibitory receptor and ligand mRNAs before and after BCG relapse (red: HLA-I decrease, n = 6; blue: HLA-I increase, n = 6). Paired, 2-tailed Student’s t test. *P < 0.05, **P < 0.005, and ****P < 0.0001.
expression, an absence of cytokine secretion upon BCG exposure and a resistance to BCG therapy in vivo are consistent with our results obtained in the human context.

Last, our findings have established for the first time to our knowledge an unexpected association between a bacterial (BCG) intracellular infection of cancer cells and a cancer immune evasion mechanism with EMT characteristics. Our data showed a direct correlation between BCG exposure, HLA-I downregulation, and distant metastasis-free survival. MB49 cells were HLA-I- and that exposure to BCG did not modify that status (24). Also de Queiroz et al. found that BCG, like TLR2, TLR4, and TLR9 agonists, could not trigger the secretion of proinflammatory cytokines from MB49 HLA-I– murine bladder carcinoma (25). Mangsbo et al. showed that in vivo in mice, therapeutic strains of BCG were inactive against established MB49 bladder tumors (26). Altogether, the fact that the transplantable syngeneic murine cell lines are cells that have acquired a loss in HLA-I expression, an absence of cytokine secretion upon BCG exposure and a resistance to BCG therapy in vivo are consistent with our results obtained in the human context.

Last, our findings have established for the first time to our knowledge an unexpected association between a bacterial (BCG) intracellular infection of cancer cells and a cancer immune evasion mechanism with EMT characteristics. Our data showed a direct correlation between BCG exposure, HLA-I downregulation,
EpCAM deficiency, and a shift toward a mesenchymal score in a subset of cancer cells. Of note, HLA-I downregulation was significantly more profound in BCG-infected cells and was associated with a type I IFN signaling pathway. A chronic type I IFN pathway has been recently described as one of the mechanisms of resistance to checkpoint blockade therapy (27). Also, the type I IFN gene signature has been established as a predictive factor for immune evasion leading to severe, uncontrolled active tuberculosis infection (28). Several mechanisms underlying the pathogenic role of type I IFN in tuberculosis have been described, including the induction of IL-10 cytokine expression and negative regulation of IL-12/IFN-γ (HLA-I requirement bypass). Conversely, patients with HLA-proficient tumors show upregulation of several immune checkpoint-inhibitory receptors (CTLA-4, PD-L1, and the ligand PD-L1, which suggests that immune checkpoint blockers such as anti–CTLA-4, anti–PD-L1, or anti-LAG3 mAbs may be active in BCG-unresponsive HLA-I+ tumors. Also, treatment strategies combining first-line intravesical BCG with systemic anti–PD-L1 mAbs are currently under investigation in the adjuvant setting (NCT03528694 and NCT03799835). Our results show that only patients without downregulation of HLA-I in their tumor upon BCG exposure would benefit from the addition of such anti–PD-L1 or anti–PD-L1 mAbs. Overall, our results offer a simple opportunity for patient stratification upon BCG immunotherapy failures based on tumor HLA-I status and provide the rationale for further investigation of distinct therapeutic strategies for those patients with HLA-I–deficient tumors.

Methods

Additional information can be found in Supplemental Methods.

**BCG reconstitution.** Bacteria used for in vitro experiments was obtained by resuspension in PBS of the lyophilized content of clinically available ImmuCyst vials.

**Ex vivo bladder tumor stimulation assay.** Freshly dissociated cells from human bladder tumors were seeded in a 96-well plate and incubated for 72 hours with or without BCG. Cells were harvested, followed by membrane and intracellular labeled according to the manufacturer’s protocol, before running them through the flow cytometer.

**Cell lines.** All human bladder cancer cell lines including RT4, SW780, HT1376, 5637, TCCSUP, and UM-UC3 were purchased from the American Type Culture Collection (ATCC, no. TCP-1020). The human A549 cell line was obtained from Nicolas Dorvault (INSERM U981, Gustave Roussy Comprehensive Cancer Center, Université Paris-Saclay, Villejuif, France). The human HeLa, HCT116, and Mel888 cell lines were obtained from Laurence Zitvogel (INSERM U1015, Gustave Roussy Comprehensive Cancer Center, Université Paris-Saclay, Villejuif, France). The murine bladder cancer cell line MB-49 was obtained from MilliporeSigma (catalog SCC148). The UPPR bladder cancer cell line was obtained from William Y. Kim (Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA).

**Cytokine and chemokine measurement.** Titration of cytokines and chemokines was performed using the Bio-Plex Pro Assays Chemokine Quick Guide protocol (Bio-Rad 27-Plex Human Chemokine Panel, kit no. M500KCAF0Y). This kit detects IL-1β, IL-1ra, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, TNF-α, IFN-γ, CXCL10, G-CSF, GM-CSF, eotaxin, CCL2, CCL3, CCL4, CCL5, VEGF, FGF basic, and PDGF-bb. Acquisitions were performed on a Bio-Plex 200 system (Bio-Rad), and analyses were done using Bio-Plex Manager 6.1 Software (Bio-Rad), respectively.
Flow cytometric analyses. For membrane labeling, TILs and cancer cells were stained with fluorochrome-coupled mAbs incubated for 20 minutes at 4°C, protected from light, and then washed with 1× PBS. Intracellular staining was performed after permeabilization with the Foxp3 Transcription Factor Staining Buffer Set (Thermo Fisher Scientific, catalog 00-5523-00) and intracellularly labeled with anti-Foxp3 mAb (eBiosciences, clone PCH101) and anti-Ki67 (BD Biosciences, catalog 556027), following the manufacturer’s protocols. Cell samples were acquired on a BD LSRFortessa X-20 flow cytometer (BD Biosciences) with single-stained Ab-capturing beads used for compensation (CompBeads, BD Biosciences, catalog 552843). For cell sorting, Zombie Aqua™ cells and anti-HLA-I and HLA-I cells after BCG coinoculation for 24 hours were sorted on a BD FACSaria III Fusion (BD Biosciences).

Data were analyzed with Kaluza Analysis software, version 2.1 (Beckman Coulter). MB49 and UPPI1541 cell lines were cultured in vitro into media with or without recombinant mouse IFN-γ (BioLegend, catalog 575306) for 24 hours and subsequently stained for HLA-I with FITC anti-mouse H-2Kb Ab (BioLegend, catalog 1165005) and run by flow cytometry.

In vitro BCG restimulation assay. Cancer cells (250,000 cells/well) were added to flat-bottomed, 6-well plates. After incubation for 24 hours at 37°C and washing with warm PBS, cancer cells were incubated with culture medium only as a negative control (2000 μL/well RPMI plus 10% heat-inactivated FBS) or BCG at a MOI of 10:1, for 24 hours. After 24 hours, the cells were washed twice with 500 μL warm 1× PBS and incubated for 6 days in culture medium with 10% serum, and the medium was changed once on day 3. Cells were harvested on day 5 using the trypsin protocol, washed twice with 1× PBS, and seeded (250,000 cells/well) in flat-bottomed, 6-well plates for 24 hours. Cells were restimulated with BCG at a MOI of 10:1. After 24 hours, supernatants were collected and stored at -20°C until cytokine measurement.

Immunofluorescence. Bladder cancer cells (5637 cell line) were grown on coverslips for 1 day before a 24-hour infection with BCG at a MOI of 10:1. Cells were washed once in PBS and fixed for 20 minutes in 4% PFA. After 3 washes in PBS, cells were blocked for 30 minutes in PBS 3% BSA at room temperature (RT). Then, nuclei were stained for 5 minutes in a 100 ng/μL DAPI solution. HLA-ABC primary Ab (Thermo Fisher Scientific, MA5-11723) was diluted up to 10 μg/μL in PBS 3% BSA and incubated overnight. After 3 washes in PBS, cells were incubated in a 1:1000 dilution of goat anti-mouse secondary Ab coupled with Alexa Fluor Plus 555 (Thermo Fisher Scientific, A32727). Cells were washed 3 times and mounted in ProLong Gold (Thermo Fisher Scientific, P36930). Confocal images were acquired on a Leica SP8, and images were analyzed with Fiji 64 bits.

Chromogenic IHC. Consecutive 3 μm thick sections of formalin-fixed, paraffin-embedded (FFPE) tumor tissues were cut on a microtome and floated on a 40°C water bath containing distilled water. Sections were transferred onto positively charged glass slides (Superfrost Plus). Slides were dried overnight and stored at 4°C until use. Consecutive FFPE slides were stained using validated and standardized protocols on Ventana Discovery Ultra or Benchmark Ultra-Auto-automated platforms (Roche Diagnostics, Ventana Medical Systems).

IHC analysis for HLA-I and PD-L1 expression. For HLA-I (clone EMR 8-5 anti-HLA class I heavy chains A, B, and C), the intensity of tumor cell membrane staining was scored using the following semiquantitative scale: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Then, the percentage of positively stained tumor cells was multiplied by the staining intensity of the tumor cell to obtain a final semiquantitative H score (score of 0–300). For PD-L1 staining (E1L3N clone, Cell Signaling Technology), primary Ab was incubated at a 1 μg/mL dilution for 1 hour at RT. Detection was performed using a HQ amplification kit and 3,3’-diaminobenzidine as a chromogen. For each tumor sample, PD-L1 expression was scored by a pathologist trained in tumor cell analysis (percentage of cells with membrane staining) and immune cells (percentage of tumor areas covered by PD-L1-expressing tumor cells).

Image analysis. Image acquisition was performed on a Virtual Slide Microscope VS120-FL (Olympus) with a ×20 air objective (0.75 NA, 345 nm/pixel). CD3+ and CD8+ lymphocytes were detected using an algorithm created in Definiens Developer software. Macrophages results are expressed as the area of CD163+ and CD68/CD163+ stained cells divided by the region of interest (ROI) area.

NanoString gene expression profiling. Isolated RNA from a human tumor specimen and cell lines were hybridized with the NanoString nCounter PanCancer Immune Profiling Human Panel CodeSet and the NanoString nCounter IO360 Panel Human Pan Panel CodeSet, respectively. RNA was quantified using the nCounter Digital Analyzer. Data were processed with nSolver Analysis Software (NanoString) using the Advanced Analysis module.

Transcriptomics (3’tag-Seq). RNA-Seq was performed on FFPE tumor RNA (100 ng) from 14 patients at baseline using 3’ Tag-Seq. We used Lexogen’s QuantSeq 3’ mRNA-Seq Library Prep Kit (Illumina). Transcriptomic data have been deposited in the NCBI’s Gene Expression Omnibus (GEO) database (GEO GSE199618).

Bioinformatics analysis. For quantification of gene expression, STAR was used to obtain the number of reads associated with each gene in the Gencode version 31 annotation (restricted to protein-coding genes, antisense, and long, intergenic noncoding RNAs [lincRNAs]). Raw counts for each sample were imported into R statistical software. The extracted count matrix was normalized to the library size to compute counts per million reads mapped (CPM) expression levels. Differential gene expression analyses in paired tissue samples before and after BCG have identified genes associated with outcomes. The Bioconductor edgR package was used to import raw counts into R statistical software. Differential expression analysis was performed using the Bioconductor limma package and the voom transformation.

ImageStream analysis. Images were captured on an Amnis ImageStream Mark II Imaging Flow Cytometer with ×40 magnification (EMD Millipore). Data were acquired and analyzed using Amnis INSPIRE software and Amnis IDEAS software, respectively.

Quantification of autophagy in U2OS cells for in vitro studies. Human osteosarcoma U2OS cells stably expressing GFP-LC3 or RFP-GFP-LC3 (PMID 21151176) were seeded at 1500 cells/well in μClear imaging plates (Greiner BioOne, Kremsmünster, Austria) and left to adapt for 24 hours before adding BCG at a MOI of 10:1, 30:1, 100:1, and 300:1. Torin (Tocris) at 0.3 μM was used as a positive control for autophagy induction. After 6 hours of incubation, cells were fixed with 3.7% paraformaldehyde (PFA) (w/v in PBS) containing 1 μg/mL Hoechst 33342 for 30 minutes. The fixative was then removed, the cells were overlaid with PBS, and the plates were sealed with adhesive aluminum tape. Images were acquired by means of an IXM confocal automated bioimager (Molecular Devices) equipped with a ×20 PlanApo objective (Nikon). Images were processed with R.

Statistics. Statistical tests were calculated in GraphPad Prism, version 8.0 (GraphPad Software). A paired, 2-tailed Student’s t test was used to compare 2 groups unless indicated otherwise, and 1-way ANOVA
was used to compare more than two groups with 1 independent variable, followed by Tukey’s correction for multiple comparisons. For Kaplan-Meier survival experiments, we performed a log-rank (Mantel-Cox) test. A P value of less than 0.05 was considered statistically significant.

Study approval. Paired tumor samples were collected from patients with high-grade NMIBC who received standard-of-care transurethral resection of the bladder tumor (TURBT) and intravesical BCG therapy at the University Paris-Saclay Hôpital Foch between January 2000 and May 2015, as previously reported (36). Study of this retrospective cohort and the associated informed consent procedures were approved by the institutional ethics committee of Hôpital Foch (IRB approval no. 00012437). In situ multidimensional profiling data (chromogenic IHC, NanoString gene expression profiling, and RNA-Seq) were generated using paired samples from pre- and post-BCG treatment tumors. Multidimensional profiling data were analyzed to identify immune correlates of BCG resistance mechanisms (Supplemental Figure 6 and Supplemental Table S). Fresh tumor samples were prospectively collected from specimens obtained from radical cystectomy procedures (n = 12) performed with curative intent at the UVSQ—University Paris-Saclay Hôpital Foch between April 2018 and September 2018. This prospective cohort was approved by the institutional ethics committee (study “mAb in vitro test,” no. ID-RCB: 2016-A00732-49).

Author contributions
MR, TL, JCS, LZ, and AM conceived and designed the study. Acquisition of data: MR, JA, CR, SM, NS, AB, MD, AKS, RC, SV, AGG, DL, ML, and NC acquired data. All authors contributed to the analysis and interpretation of data and to critical revision of the manuscript. MR wrote the manuscript. MR and TZT performed statistical analyses. DB provided administrative and technical support, and CR provided material support.

Acknowledgments
The authors thank Alice Perchenet and Laetitia Grynszpan for technical support and William Y. Kim (University of North Carolina) for providing the UPPL1541 murine bladder cancer cell line. MR is supported by the Fondation Foch and the Association Française d’Urologie (AFU). AM is supported by the Fondation MSD Avenir, Fondation Gustave Roussy, SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) and INSERM CIC1428. AGG is supported by the Fondation pour la Recherche Médicale (FRM). NA is supported by the National Cancer Institute (NCI), NIH grant U01CA247573. GK is supported by the Ligue contre le Cancer (équipe labellisée); the Agence Nationale de la Recherche (ANR) – Projets blancs; the AMMICA US23/CNRS UMS3655; the Association pour la recherche sur le cancer (ARC); Cancéroplège Ile-de-France; the FRM; a donation by Elior; Equipus Oncop-Pheno-Screen; the European Joint Programme on Rare Diseases (EJP-RT); Gustave Roussy Odysea, the European Union Horizon 2020 Projects Oncobiome and Crimson; the Fondation Carrefour; the Institut National du Cancer (INCa); the Institut Universitaire de France; LabEx Immuno – Oncology (ANR-18-IDEX-0001); the Leduq Foundation; a Cancer Research ASPIRE Award from the Mark Foundation; the RHU Torino Lumière; the Seerave Foundation; SIRIC (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CAREPM). This study contributes to the IDEX Université de Paris ANR-18-IDEX-0001. AB and MD are supported by ANR-10-IAHU-01.

Address correspondence to: Mathieu Rouanne, Microbiology and Immunology Department, Columbia University, 701 West 168th Street, New York, New York 10032, USA. Phone: 1646.409.4908; Email: rouanne.mathieu@gmail.com; mr4104@cumc.columbia.edu. Or to: Aurélien Marabelle, Gustave Roussy Cancer Center and Université Paris Saclay, 114 rue Édouard Vaillant, 94805 Villejuif, France. Phone: 33.626097137; Email: aurélien.marabelle@gustaveroussy.fr. AK’s present address is: Urology Research Unit, Département d’Urologie (AFU). AM is supported by the Fondation MSD Avenir, the Foundation Gustave Roussy, BNP Paribas Foundation, Leducq Foundation; the Leducq Foundation; the Seerave Foundation of the RHU Torino Lumière; the Seerave Foundation; SIRIC (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CAREPM). This study contributes to the IDEX Université de Paris ANR-18-IDEX-0001. AB and MD are supported by ANR-10-IAHU-01.


